Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 123 results:
Author Title Type [ Year] Filters: Author is Tsapas, Apostolos [Clear All Filters]
Canagliflozin in the treatment of type 2 diabetes: an evidence-based review of its place in therapy.
Core Evidence. Volume 12, 1 - 10.
(2017). Canagliflozin in the treatment of type 2 diabetes: an evidence-based review of its place in therapy..
Core Evid. 12, 1-10.
(2017). Diagnostic Accuracy of Fecal Immunochemical Test in Patients at Increased Risk for Colorectal Cancer.
JAMA Internal Medicine. 177(8), 1110.
(2017). Evaluation of the Greek TranQol: a novel questionnaire for measuring quality of life in transfusion-dependent thalassemia patients..
Ann Hematol. 96(11), 1937-1944.
(2017). Evaluation of the Greek TranQol: a novel questionnaire for measuring quality of life in transfusion-dependent thalassemia patients.
Annals of Hematology. 9635386959511886953716410511460363056271262012394215457(1111435131343Suppl 21151168618233445), 1937 - 1944.
(2017). Fixed ratio combinations of glucagon like peptide 1 receptor agonists with basal insulin: a systematic review and meta-analysis..
Endocrine. 56(3), 485-494.
(2017). Fixed ratio combinations of glucagon like peptide 1 receptor agonists with basal insulin: a systematic review and meta-analysis.
Endocrine. 5625815134372239371731583439396341596(31134341111109129114943), 485 - 494.
(2017). Meta-analysis of artificial pancreas trials: methodological considerations.
The Lancet Diabetes & Endocrinology. 5(9), 685.
(2017). Meta-analysis of artificial pancreas trials: methodological considerations..
Lancet Diabetes Endocrinol. 5(9), 685.
(2017). Once-weekly dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a systematic review and meta-analysis.
Expert Opinion on Pharmacotherapy. 18555857646565(9111111), 843 - 851.
(2017). Once-weekly dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a systematic review and meta-analysis..
Expert Opin Pharmacother. 18(9), 843-851.
(2017). Artificial pancreas treatment for outpatients with type 1 diabetes: systematic review and meta-analysis..
BMJ. 361, k1310.
(2018). Artificial pancreas treatment for outpatients with type 1 diabetes: systematic review and meta-analysis.
BMJ. k1310.
(2018). Cost-Effectiveness of Empagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus at Increased Cardiovascular Risk in Greece.
Clinical Drug Investigation. 3831184061314132015410373121437191919154637191436(511Suppl 2518942221193773988), 417 - 426.
(2018). Cost-Effectiveness of Empagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus at Increased Cardiovascular Risk in Greece..
Clin Drug Investig. 38(5), 417-426.
(2018). In type 2 diabetes, weekly semaglutide reduced HbA 1c and increased weight loss more than weekly exenatide ER.
Annals of Internal Medicine. 168(8), JC46.
(2018). In type 2 diabetes, weekly semaglutide reduced HbA1c and increased weight loss more than weekly exenatide ER..
Ann Intern Med. 168(8), JC46.
(2018). Possible mechanisms of direct cardiovascular impact of GLP-1 agonists and DPP4 inhibitors..
Heart Fail Rev. 23(3), 377-388.
(2018). Possible mechanisms of direct cardiovascular impact of GLP-1 agonists and DPP4 inhibitors.
Heart Failure Reviews. 377 - 388.
(2018). Preferred reporting items for overviews of systematic reviews including harms checklist: a pilot tool to be used for balanced reporting of benefits and harms..
J Clin Epidemiol. 93, 9-24.
(2018). Preferred reporting items for overviews of systematic reviews including harms checklist: a pilot tool to be used for balanced reporting of benefits and harms.
Journal of Clinical Epidemiology. 93, 9 - 24.
(2018). Semaglutide for type 2 diabetes mellitus: a systematic review and meta-analysis.
Diabetes, Obesity and Metabolism.
(2018). Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis..
Diabetes Obes Metab. 20(9), 2255-2263.
(2018).
(2018). Decreased cortisol response to low-dose Synacthen test in pediatric patients with type 1 diabetes..
J Diabetes. 11(9), 773-774.
(2019).